In a report issued on March 30, Joseph Vruwink from Robert W. Baird maintained a Buy rating on Phreesia (PHR – Research Report), with a price target of $51.00. The company’s shares closed last Thursday at $26.36, close to its 52-week low of $22.89.
According to TipRanks.com, Vruwink is a 3-star analyst with an average return of 2.7% and a 45.2% success rate. Vruwink covers the Technology sector, focusing on stocks such as Manhattan Associates, Instructure Holdings, and Bentley Systems.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Phreesia with a $43.88 average price target, implying a 62.5% upside from current levels. In a report released yesterday, JMP Securities also maintained a Buy rating on the stock with a $50.00 price target.
Phreesia’s market cap is currently $1.51B and has a P/E ratio of -18.15.
Based on the recent corporate insider activity of 73 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of PHR in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Phreesia, Inc. provides patient check-in solutions for medical practices. It provides solutions that transform the healthcare experience by engaging patients in their care and enabling healthcare provider organizations to optimize operational efficiency, improve profitability and enhance clinical care. Through the SaaS-based Phreesia Platform the company offers healthcare provider organizations a robust suite of solutions to manage the patient intake process and a payments solution for secure processing of patient payments. Its platform also provides life sciences companies with an engagement channel for targeted and direct communication with patients. Phreesia was founded by Chaim Indig and Evan Roberts in January 2005 and is headquartered in New York, NY.
Read More on PHR:
- Analysts Have Conflicting Sentiments on These Consumer Goods Companies: MSA Safety (MSA) and Arhaus (ARHS)
- Analysts Offer Insights on Healthcare Companies: Replimune Group (REPL), Immunovant (IMVT) and Graybug Vision (GRAY)
- Analysts’ Opinions Are Mixed on These Services Stocks: Medpace Holdings (MEDP) and Centogene NV (CNTG)
- Evercore ISI Believes Apple (AAPL) Won’t Stop Here
- Evercore ISI Sticks to Their Buy Rating for Savara (SVRA)